The designation supports Gene Solutions’ US development pathway for its multi-omic blood-based test designed to detect cancer-associated signals across 10 cancer types. ...
Open-access digital platform supports policymakers, researchers and the public in exploring the health, economic and education impacts of pandemic response strategies....
POWER CAD I study will evaluate feasibility of the Pulse IVL™ system in patients with severely calcified coronary arterial disease...
RAMP UP programme with Hitachi High-Tech America supports electronic genome mapping studies in AML and MDS ...
Collaboration aims to improve accessibility and adoption of multi-cancer early detection solutions through a broader practitioner network ...
Investment manager Michael Lamprecht highlights structural funding gaps, regulatory fragmentation, and the need for commercially viable antimicrobial resistance strategies ...
The launch of pTau217 marks a significant step in providing a simple, blood-based tool to diagnose Alzheimer's much earlier in the patient journey...
The FDA 510(k) clearance advances Biozen’s BP1000, a handheld fingertip device designed to deliver clinically validated spot blood pressure measurements without an arm cuff or per-user calibration. ...
The event highlighted healthcare AI’s shift from experimentation to real-world deployment, with discussions on accountability, governance, workforce readiness and exhibitor solutions including Heidi and AITRICS-VC....
The NMPA designation advances NHWD-870 HCI, an oral BET inhibitor for advanced thoracic NUT carcinoma, following Phase II data showing anti-tumour activity and survival benefit in a rare, aggressive cancer with limited treatment options. ...
